Results of the Votes of the Combined Shareholders’ General Meeting of May 22, 2025

Core Points - Inventiva, a clinical-stage biopharmaceutical company, focuses on developing oral therapies for metabolic dysfunction-associated steatohepatitis (MASH) [1][11] - The Combined Shareholders' Meeting took place on May 22, 2025, where all resolutions were adopted except for one [2][3] - The compensation policy for corporate officers was approved as presented in the 2024 Universal Registration Document [4] Voting Results - A total of 245 shareholders participated in the voting, representing 90,772,892 shares, which is 65.264% of the voting rights [5][7] - The majority of ordinary resolutions were adopted with over 99% approval, while the only rejected resolution was the 33rd, which aimed to empower the Board of Directors for share capital increases [3][10] - The voting results showed a high level of shareholder engagement, with a quorum of 65.264% achieved [5][10] Company Overview - Inventiva is publicly listed on Euronext Paris and Nasdaq, focusing on unmet medical needs in liver diseases [11][12] - The company is currently evaluating lanifibranor in a pivotal Phase 3 clinical trial for MASH [11]